MarketBeat
11 Aug 2026, 06:02 UTC · 3h ago
Tenax LEVEL Trial Misses Primary Goal, but Subgroup Data Bolsters Levosimendan Case
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
MarketBeat
11 Aug 2026, 06:02 UTC · 3h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
5 claims · each scored for market impact
Tenax Therapeutics' Phase III LEVEL trial of oral levosimendan failed to meet its primary endpoint of change in six-minute walk distance. — Failure to meet a primary endpoint in a Phase III trial is a major setback for drug approval and typically leads to a significant drop in stock price.
-0.90The key secondary endpoint, the Kansas City Cardiomyopathy Questionnaire total symptom score, also failed to reach statistical significance. — Failure of both primary and key secondary endpoints reinforces the lack of efficacy across the general study population.
-0.70Tenax identifies a treatment effect in a subgroup of patients with more advanced disease (baseline walk distance < 333 meters) and higher baseline NT-proBNP levels. — While providing a potential path forward via a narrower patient population, these are post-hoc nominal p-values and not as robust as a successful primary endpoint.
+0.30Continue reading
6 related stories
Top 1 mover · tap to explore
Treatment-related adverse events occurred in 38% of the levosimendan group compared to 17% in the placebo group. — A higher rate of treatment-related adverse events increases the risk profile and potential for future safety concerns during regulatory review.
-0.20The company plans to request FDA and EMA consultations to evaluate amending the LEVEL-2 trial or launching a new trial with stricter enrollment criteria. — Indicates the program is continuing rather than being abandoned, but introduces significant regulatory uncertainty and additional time/cost.
+0.10Which stocks this story touches
The company's Phase III LEVEL trial failed to meet its primary endpoint for oral levosimendan.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Proactive Investors
1d ago
